IL-7 restores lymphocyte functions in septic patients

Area of Science:

• Immunology
• Critical Care Medicine
• Molecular Biology

Background:

• Sepsis is a leading cause of death, characterized by severe lymphocyte dysfunction.
• This dysfunction increases mortality risk and susceptibility to secondary infections in critically ill patients.

Purpose of the Study:

• To investigate the potential of recombinant human IL-7 (rhIL-7) as a therapy for sepsis-induced lymphocyte dysfunction.
• To assess the impact of rhIL-7 on immune cell function in septic shock patients.

Main Methods:

• Measured IL-7 pathway components (IL-7, soluble CD127, cellular CD127) in septic patients.
• Performed ex vivo stimulation of lymphocytes from septic patients with rhIL-7.
• Assessed lymphocyte proliferation, IFN-γ production, STAT5 phosphorylation, and BCL2 induction.

Main Results:

• The IL-7 pathway in septic patients remains activable.
• Ex vivo rhIL-7 treatment significantly enhanced CD4(+) and CD8(+) lymphocyte proliferation.
• rhIL-7 improved IFN-γ production, STAT5 phosphorylation, and BCL2 induction in patient lymphocytes.

Conclusions:

• rhIL-7 effectively restores lymphocyte functionality in septic patients.
• These findings provide a strong rationale for clinical trials of rhIL-7 in septic shock.
• This represents the first report demonstrating rhIL-7's ability to normalize lymphocyte functions in sepsis.